| Business

Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Diamyd, with R&D here, inks $625M deal with J&J

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Staff and Wire Reports
Wednesday, June 23, 2010

Diamyd Medical AB, a Stockholm, Sweden-based company that maintains its research and development facilities in Pittsburgh, secured a major deal with a unit of Johnson & Johnson to develop and commercialize Diamyd's diabetes therapy.

The agreement over time could be worth more than $625 million to Ortho-McNeil-Janssen Pharmaceuticals Inc., the company said.

Diamyd came to Pittsburgh in 2005 when it acquired Nurel Therapeutics, founded by University of Pittsburgh scientists.

Darren Wolfe, CEO of Diamyd Inc. USA, said his R&D unit has more than doubled its work force in the last six months, to seven, and expects to employ 10 to 12 people within a year.

The company is housed within the Pittsburgh Life Sciences Greenhouse incubator at the Pittsburgh Technology Center in South Oakland. The Greenhouse also is an investor in Diamyd, having placed $100,000 in the local operations.

Subscribe today! Click here for our subscription offers.



Show commenting policy

Most-Read Business